Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

14:33
10/09/16
10/09
14:33
10/09/16
14:33

Merck reports interim KEYNOTE-052 data on Keytruda in urothelial cancer

Merck announced "positive" findings from the phase 2 KEYNOTE-052 study investigating the use of Keytruda in previously untreated patients with unresectable or metastatic urothelial cancer who are ineligible for cisplatin-based therapy. Data presented at the ESMO 2016 Congress showed an overall response rate of 24 percent in the total study population, which included patients with and without PD-L1 expression. Findings presented at ESMO 2016 are from the planned interim analysis of the first 100 patients, which was intended to evaluate ORR and determine the PD-L1-high expression cut-point as examined by expression in tumor and immune cells. Forty-five percent of patients had an Eastern Cooperative Oncology Group Performance Status score of two, 30 percent had a PS score of one, and 24 percent had a PS score of zero. In the total study population, ORR was 24 percent with a complete response rate of six percent. Review of the outcomes based on PD-L1 expression showed that in patients with PD-L1 expression of less than one percent, ORR was 18 percent with a complete response rate of three percent; in patients with PD-L1 expression greater than or equal to one percent and less than 10 percent, ORR was 15 percent with no complete responses; and, in patients expressing PD-L1 at levels equal to or greater than 10 percent, ORR was 37 percent with a complete response rate of 13 percent. Among the 24 percent of patients in the total study population who were responding to treatment, the median duration of response had not been reached -- range 1.4+ to 9.8+ months -- with 83 percent of patients having responses of six months or longer. The safety profile of Keytruda was consistent with that observed in previously reported studies. Five patients discontinued due to a treatment-related adverse event; there were no treatment-related deaths.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

AAPL

Apple

$146.28

0.65 (0.45%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

13:47
06/24/17
06/24
13:47
06/24/17
13:47
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$146.28

0.65 (0.45%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

MSFT

Microsoft

$71.21

0.95 (1.35%)

IBM

IBM

$154.11

-0.29 (-0.19%)

MA

MasterCard

$124.01

0.71 (0.58%)

ORCL

Oracle

$50.95

0.65 (1.29%)

VMW

VMware

$90.92

0.48 (0.53%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AKAM

Akamai

$51.30

1.28 (2.56%)

SAP

SAP

$107.48

0.42 (0.39%)

QCOM

Qualcomm

$56.91

0.44 (0.78%)

ADBE

Adobe

$145.41

1.72 (1.20%)

ACN

Accenture

$122.74

0.66 (0.54%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

CYH

Community Health

$9.33

0.06 (0.65%)

THC

Tenet

$18.52

-0.38 (-2.01%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

UHS

Universal Health

$115.43

0.22 (0.19%)

AET

Aetna

$152.10

-0.88 (-0.58%)

WCG

WellCare

$183.28

-0.32 (-0.17%)

CI

Cigna

$169.61

-1.07 (-0.63%)

HUM

Humana

$238.42

1.42 (0.60%)

ANTM

Anthem

$190.17

-3.19 (-1.65%)

HNT

Health Net

CNC

Centene

$84.15

1.15 (1.39%)

MOH

Molina Healthcare

$71.33

0.02 (0.03%)

UNH

UnitedHealth

$185.25

-1.25 (-0.67%)

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

X

U.S. Steel

$22.25

1.18 (5.60%)

AKS

AK Steel

$6.65

0.35 (5.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 02

    Aug

  • 14

    Aug

  • 23

    Oct

  • 03

    Feb

ARQL

ArQule

$1.17

0.03 (2.63%)

, NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
European Hematology Association to hold a conference »

22nd Congress of the EHA…

ARQL

ArQule

$1.17

0.03 (2.63%)

NLNK

NewLink Genetics

$7.36

-0.04 (-0.54%)

BLUE

bluebird bio

$112.00

-6.5 (-5.49%)

XLRN

Acceleron

$34.10

0.15 (0.44%)

BLCM

Bellicum Pharmaceuticals

$13.39

-0.59 (-4.22%)

CRSP

CRISPR Therapeutics

$16.44

0.3 (1.86%)

AGIO

Agios Pharmaceuticals

$59.18

1.76 (3.07%)

CELG

Celgene

$134.31

0.63 (0.47%)

STML

Stemline

$9.10

0.6 (7.06%)

CTIX

Cellceutix

KPTI

Karyopharm

$9.97

0.01 (0.10%)

RARX

RA Pharmaceuticals

$23.01

0.01 (0.04%)

CDTX

Cidara Therapeutics

$6.70

-0.2 (-2.90%)

GBT

Global Blood Therapeutics

$29.85

0.6 (2.05%)

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

TGTX

TG Therapeutics

$11.95

-0.05 (-0.42%)

VSTM

Verastem

$2.32

-0.06 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 24

    Jun

  • 27

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 11

    Jul

  • 26

    Sep

HIMX

Himax

$8.17

-0.02 (-0.24%)

04:55
06/24/17
06/24
04:55
06/24/17
04:55
Conference/Events
Himax management to meet with Roth Captial »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

ANTM

Anthem

$190.17

-3.19 (-1.65%)

18:58
06/23/17
06/23
18:58
06/23/17
18:58
Periodicals
Anthem to pay $115M to settle data breach lawsuits, Reuters reports »

Anthem has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVU

Supervalu

$2.94

-0.04 (-1.34%)

18:26
06/23/17
06/23
18:26
06/23/17
18:26
Hot Stocks
Supervalu completes acquisition of Unified Grocers »

Supervalu announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$70.52

0.04 (0.06%)

18:14
06/23/17
06/23
18:14
06/23/17
18:14
Periodicals
Gilead no longer a 'value trap,' Barron's reports »

Consistent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

, EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

18:07
06/23/17
06/23
18:07
06/23/17
18:07
Hot Stocks
Southern National Bancorp, Eastern Virginia Bankshares complete merger »

Southern National Bancorp…

SONA

Southern National Bancorp

$17.21

0.11 (0.64%)

EVBS

Eastern Virginia Bankshares

$11.01

0.14 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAC

IAC

$104.84

0.3 (0.29%)

17:56
06/23/17
06/23
17:56
06/23/17
17:56
Hot Stocks
IAC will not pursue plan to create new class of non-voting stock »

IAC's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGL

Engility

$27.37

0.26 (0.96%)

17:50
06/23/17
06/23
17:50
06/23/17
17:50
Hot Stocks
Engility to eliminate position of president, COO »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

ADM

Archer Daniels

$41.16

0.13 (0.32%)

17:48
06/23/17
06/23
17:48
06/23/17
17:48
Hot Stocks
ADM Animal Nutrition recalls Rough-N-Ready cattle feed over monensin concerns »

ADM Animal Nutrition, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOYA

Voya Financial

$35.24

0.03 (0.09%)

17:30
06/23/17
06/23
17:30
06/23/17
17:30
Syndicate
Breaking Syndicate news story on Voya Financial »

Voya Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

, TBK

Triumph Bancorp

17:19
06/23/17
06/23
17:19
06/23/17
17:19
Hot Stocks
Independent Bank to sell nine Colorado branches to TBK Bank »

Independent Bank (IBTX)…

IBTX

Independent Bank

$54.85

-1.1 (-1.97%)

TBK

Triumph Bancorp

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

WUBA

58.com

$43.30

0.87 (2.05%)

17:11
06/23/17
06/23
17:11
06/23/17
17:11
Hot Stocks
Breaking Hot Stocks news story on 58.com »

General Atlantic reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

, LGF.B

Lionsgate

$25.38

0.34 (1.36%)

17:10
06/23/17
06/23
17:10
06/23/17
17:10
Hot Stocks
Box Office Battle: 'Transformers' expected to top 'Cars 3,' 'Wonder Woman' »

Viacom (VIA, VIAB)…

FOXA

21st Century Fox

$27.19

0.22 (0.82%)

LGF.B

Lionsgate

$25.38

0.34 (1.36%)

DIS

Disney

$104.36

0.14 (0.13%)

VIAB

Viacom

$34.11

-0.01 (-0.03%)

LGF.A

Lionsgate

$27.07

0.31 (1.16%)

VIA

Viacom

$39.15

0.1 (0.26%)

SNE

Sony

$38.52

0.11 (0.29%)

FOX

21st Century Fox

$26.93

0.3 (1.13%)

TWX

Time Warner

$99.70

0.3 (0.30%)

CMCSA

Comcast

$39.50

-0.44 (-1.10%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 27

    Jul

  • 03

    Aug

  • 08

    Aug

NVUS

Novus Therapeutics

$6.00

-0.04 (-0.66%)

17:07
06/23/17
06/23
17:07
06/23/17
17:07
Syndicate
Breaking Syndicate news story on Novus Therapeutics  »

Novus Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXG

Interpace Diagnostics

$0.88

0.03 (3.53%)

17:05
06/23/17
06/23
17:05
06/23/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Interpace Diagnostics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$14.95

0.26 (1.77%)

17:02
06/23/17
06/23
17:02
06/23/17
17:02
Hot Stocks
Monmouth Real Estate acquires building in Texas for $50.6M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

ARCW

ARC Group

$3.55

0.15 (4.41%)

17:01
06/23/17
06/23
17:01
06/23/17
17:01
Hot Stocks
ARC Group names Drew Kelley as Interim CEO, effective July 1 »

ARC Group Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAVM

PAVmed

$4.41

-0.08 (-1.78%)

16:55
06/23/17
06/23
16:55
06/23/17
16:55
Syndicate
PAVmed announces effectiveness of Form S-1 resale registration statement »

PAVmed announced that on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFSF

MutualFirst Financial

$36.15

0.9 (2.55%)

16:48
06/23/17
06/23
16:48
06/23/17
16:48
Hot Stocks
MutualFirst Financial senior executives enter 10b5-1 trading plans »

On June 23, David Heeter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$32.10

0.25 (0.78%)

16:46
06/23/17
06/23
16:46
06/23/17
16:46
Hot Stocks
Cisco CEO Charles Robbins enters 10b5-1 trading plan »

On June 21, Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 12

    Jul

  • 12

    Jul

  • 13

    Jul

  • 16

    Aug

SITO

SITO Mobile

$3.66

0.02 (0.55%)

16:43
06/23/17
06/23
16:43
06/23/17
16:43
Hot Stocks
SITO Mobile chairman Paul Pressler resigns »

Effective as of June 23,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REGN

Regeneron

$517.33

-9.2 (-1.75%)

, CELG

Celgene

$134.31

0.63 (0.47%)

16:41
06/23/17
06/23
16:41
06/23/17
16:41
General news
S&P sees mild weekly gain, Nasdaq outperforms as biotech shines »

The S&P finished the…

REGN

Regeneron

$517.33

-9.2 (-1.75%)

CELG

Celgene

$134.31

0.63 (0.47%)

GILD

Gilead

$70.54

0.06 (0.09%)

BIIB

Biogen

$280.32

-0.25 (-0.09%)

VRTX

Vertex

$133.50

-2.03 (-1.50%)

AMGN

Amgen

$172.50

-1.32 (-0.76%)

ABBV

AbbVie

$72.64

-0.54 (-0.74%)

ALXN

Alexion

$126.07

-0.16 (-0.13%)

BA

Boeing

$202.23

2.79 (1.40%)

ORCL

Oracle

$50.95

0.65 (1.29%)

EQT

EQT Corporation

$56.19

4.16 (8.00%)

RICE

Rice Energy

$25.65

1.62 (6.74%)

SYK

Stryker

$141.12

-0.1 (-0.07%)

NVDQ

Novadaq

$11.78

-0.02 (-0.17%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

LH

LabCorp

$151.62

1.28 (0.85%)

ICLR

ICON plc

$96.37

-0.26 (-0.27%)

NKE

Nike

$52.85

0.45 (0.86%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

INTC

Intel

$34.19

-0.17 (-0.49%)

AMD

AMD

$14.15

-0.23 (-1.60%)

LZB

La-Z-Boy

$32.30

0.7 (2.22%)

RHT

Red Hat

$99.42

0.54 (0.55%)

AAL

American Airlines

$48.63

-0.34 (-0.69%)

HCA

HCA Holdings

$86.24

0.1 (0.12%)

LPNT

LifePoint

$65.50

-1.6 (-2.38%)

THC

Tenet

$18.52

-0.38 (-2.01%)

SCS

Steelcase

$13.65

-0.45 (-3.19%)

ACN

Accenture

$122.74

0.66 (0.54%)

BBBY

Bed Bath & Beyond

$29.65

-4.09 (-12.12%)

BBRY

BlackBerry

$9.71

-1.35 (-12.21%)

BAC

Bank of America

$22.82

-0.11 (-0.48%)

C

Citi

$63.41

-0.21 (-0.33%)

GS

Goldman Sachs

$217.19

-2.58 (-1.17%)

JPM

JPMorgan

$86.86

-0.16 (-0.18%)

MS

Morgan Stanley

$43.69

-0.92 (-2.06%)

WFC

Wells Fargo

$52.45

-0.04 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

  • 29

    Jun

  • 06

    Jul

  • 07

    Jul

  • 13

    Jul

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 14

    Aug

  • 29

    Aug

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 23

    Oct

  • 14

    Nov

  • 15

    Jan

  • 03

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:39
06/23/17
06/23
16:39
06/23/17
16:39
General news
Moody's raises Greece rating to Caa2 from Caa3, outlook to positive from stable »

Moody's has upgraded…

CFCO

CF Corporation

$11.42

-0.04 (-0.35%)

16:38
06/23/17
06/23
16:38
06/23/17
16:38
Hot Stocks
Breaking Hot Stocks news story on CF Corporation »

Mason Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.